Builds on company’s more than $3b U.S. investment since 2018 which created thousands of new jobs across 44 states ...

Thursday 30 October, Riyadh – CSL Seqirus and Vaccine Industrial Company, have signed a Memorandum of Understanding with the Ministry of Health of Saudi Arabia to enhance the biotechnology sector by ...

Purpose-built to optimise the production of plasma-derived therapies for conditions such as immunodeficiencies, neurological disorders, and burns, the Broadmeadows facility combines cutting-edge ...

Summit, New Jersey, USA | 21 October, 2025 – CSL Seqirus, a global leader in seasonal influenza prevention (ASX: CSL), has shared new actionable real-world evidence (RWE) reinforcing the critical role ...

Summit, New Jersey, USA | 17 October 2025 – CSL Seqirus, a business of CSL (ASX:CSL) today announced that it will be presenting 14 abstracts at the European Scientific Working group on Influenza ...

Melbourne, Australia – 17 October 2025 – CSL has announced that the Science Based Targets initiative (SBTi) has approved CSL’s near-term science-based emissions reduction targets. These are: CSL ...

OTTAWA, Ontario, Oct. 6, 2025 /PRNewswire/ -- CSL Behring Canada Inc., a business unit of global biopharma leader CSL, today announced that it has signed a Letter of Intent (LOI) with the pan-Canadian ...

ST. GALLEN, Switzerland, and SAN DIEGO, Sept. 26, 2025 /PRNewswire/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) support the recent publication of the updated clinical practice ...

ANDEMBRY is the first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks in people with HAE The authorization of ANDEMBRY expands CSL's HAE franchise and underscores ...

MELBOURNE, Aug. 18, 2025 /PRNewswire/ -- Global biotherapeutics leader CSL today announced a reported net profit after tax of US$3.0 billion for the 12 months ended 30 June 2025, up 17% on a constant ...

ANDEMBRY inhibits the top of the HAE cascade by targeting factor XIIa and provides sustained protection from attacks Once-monthly dosing reduced HAE attacks by a median of more than 99 percent and a ...